June 2019 Edition

* Supporting the Joint Commissions New EPs * Transitions of Care - CE Expires Soon! * June Webinar: Reversal Guidance from the AC Forum * Centers of Excellence Literature Updates * Denver Boot Camp*

---

**Supporting the Joint Commission's New EPs**

Six new Anticoagulant Therapy elements of performance (EPs) within the National Patient Safety Goal (NPSG) 03.05.01 go into effect on **July 1, 2019**.

The Joint Commission and the Anticoagulation Forum developed a two-part webinar series to share best practices and answer questions about implementation. This webinar series provided insights on implementation within health care settings to successfully achieve established targets.

Part 1 was recorded on April 2 and covered EPs 1-4; Part 2 was recorded on May 7 and covered EPs 4-8. **Recordings and slide decks** for both sessions are now available on the Joint Commission website.

The AC Forum has also cataloged all resources that can support this implementation within our Centers of Excellence Resource Center. To learn more about how to find these resources click on "NPSG Elements" in the menu on the **Resource Center**.

---

**FREE CE: Transitions of Care Summit**

Credit only available one more week!

This unique program was only offered at our Austin 2018 Boot Camp. The program outlines why anticoagulation patients are at increased risk when changing care settings, complexities in care, and best practices for discharge. This enduring material carries a total of 3.25 contact hours of credit and is available **until June 25, 2019**.

**Take Course**

---

**Reversal of Direct Oral Anticoagulants:**

**Guidance from the Anticoagulation Forum**

**Thursday | June 20, 2019 | 12:00 PM ET**

**Guest Speakers:** Adam Cuker, MD and Allison Burnett, PharmD

**Presenter:** Sara Vazquez, PharmD
We are pleased to announce **FREE Open Access to this document**, published in the *American Journal of Hematology*, April 2019.

The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.

---

**Centers of Excellence Resource Center**

**Literature Updates: Spotlight on Bleeding**

Have you visited our Literature Updates recently? This bi-weekly update has been our most popularly access resource since it’s release.

The most recent list was published on June 10. Dozens of articles are highlighted with each release; below are just a few:

- Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban.
- EMA reviews bleeding risk with direct oral anticoagulants.
- Risk of bleeding in patients undergoing pulmonary procedures on antiplatelet or anticoagulants: A systematic review.

[Link to Literature Updates]

---

**Denver Boot Camp | The Grand Hyatt | October 10-11, 2019**

**Why Boot Camp?**

In two days you will experience a comprehensive curriculum covering essentials of anticoagulation, exploration of various disease states, drug management and discussions around quality measures. Whether you are new to the field of anticoagulation or a seasoned practitioner, Boot Camp will help improve your current practice.

**Benefits of this course:**

- Great opportunity for prep for the NCBAP CACP exam or other certification exam
- Continuing education credits (approximately 11 hours) for Pharmacy, Physicians and Nurses
- Updates on the latest in guidance, unique patient pops & special situations
- Opportunity to network with colleagues

[Link to Register]

---

**AC Forum Experts in July Edition of JTT**
Former board and current advisory council members Renato Lopes, MD, PhD and Daniel Witt, PharmD have articles featured in the July edition of *Journal of Thrombosis and Thrombolysis*. Take a look today:

- **International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.**
- **Understanding patients’ care barriers in the treatment of venous thromboembolism.**

---

**Thank you to our newsletter sponsors**

![Janssen][1]
![Portola Pharmaceuticals][2]
![Bristol-Myers Squibb][3]
![Pfizer][4]
![Roche][5]